Expects to Report EVOMELA® (melphalan for injection) Fourth Quarter 2021 Unaudited Revenue of Approximately $9.12 Million and Full-Year 2021 Unaudited Revenue of Approximately $30 Million, exceeding guidance
Pipeline Assets Continue to Progress, NMPA Granted CTA Approval for BI-1206; CID-103 Phase 1 Enrolling Patients at French and UK Sites
PR Newswire
ROCKVILLE, Md. and BEIJING, Feb. 16, 2022